Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide is a synthetic small molecule dipeptide, structurally characterized by a central proline moiety, a terminal cycloheptyl group, and a benzamidine-type (carbamimidoyl) substituent. It was developed as part of a congeneric series of trypsin inhibitors for biochemical research. The compound binds to the S3/S4 specificity pocket of trypsin and related serine proteases, acting as an inhibitor by occupying the active site and blocking substrate access. Its mechanism involves competitive inhibition at the orthosteric site of trypsin. This molecule has been studied primarily in structural biology and enzymology contexts rather than clinical development[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide.